ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
What causes high hematocrit? High DHT?
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 41242" data-attributes="member: 3"><p>Elevated Dihydrotestosterone is Associated with Testosterone-Induced Erythrocytosis</p><p></p><p></p><p> Aghazadeh, Monty et al. The Journal of Urology </p><p></p><p>Abstract </p><p></p><p></p><p>Introduction Erythrocytosis is the most common dose-limiting adverse effect of testosterone therapy (TTh), but the mechanisms of T-mediated erythropoiesis remain unclear. In this study, we examine risk factors for erythrocytosis associated with TTh. Methods Retrospective review of 179 hypogonadal men on TTh in a single andrology clinic was performed. Demographic data, TTh formulation and duration of treatment, and 5&#945; reductase inhibitor (5ARI) use were assessed. Serum dihydrotestosterone (DHT), total T (TT), free T (FT), follicle stimulating hormone (FSH), luteinizing hormone (LH), Hematocrit (Hct), and lipid levels were extracted and changes during treatment determined. Spearman's rank correlation was used to identify relationships between change in Hct (&#916;Hct) and study variables. Results Of 179 patients, 49 (27%) developed a &#8805;10% &#916;Hct and 36 (20.1%) developed erythrocytosis (Hct &#8805;50%) at a median follow-up of 7 months. Topical gels were used by 41.3% of patients, injectable T by 52.5%, and subcutaneous pellets by 6.1%. More men who developed &#916;Hct &#8805;10% used injectable T than men with &#916;Hct <10% (65% vs. 48%, p=0.035), and were less likely to be on 5ARI (2% vs. 15%, p=0.017). Men with &#916;Hct &#8805;10% had higher post-treatment DHT levels (605.0 vs. 436.0 ng/dL, p=0.017) and lower LH and FSH levels than men with &#916;Hct <10%. Spearman's rank correlations yielded relationships between &#916;Hct and post-treatment DHT (&#961;=0.258, p=0.001) and TT (&#961;=0.171, p=0.023). Conclusion DHT may play a role in TTh-related erythrocytosis, and monitoring of DHT levels during TTh should be considered. In men who develop erythrocytosis, 5ARIs may be therapeutic.</p><p></p><p>Read more at: <a href="https://www.excelmale.com/forum/showthread.php?137-How-to-Manage-Polycythemia-Caused-by-Testosterone-Replacement-Therapy" target="_blank">https://www.excelmale.com/forum/showthread.php?137-How-to-Manage-Polycythemia-Caused-by-Testosterone-Replacement-Therapy</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 41242, member: 3"] Elevated Dihydrotestosterone is Associated with Testosterone-Induced Erythrocytosis Aghazadeh, Monty et al. The Journal of Urology Abstract Introduction Erythrocytosis is the most common dose-limiting adverse effect of testosterone therapy (TTh), but the mechanisms of T-mediated erythropoiesis remain unclear. In this study, we examine risk factors for erythrocytosis associated with TTh. Methods Retrospective review of 179 hypogonadal men on TTh in a single andrology clinic was performed. Demographic data, TTh formulation and duration of treatment, and 5α reductase inhibitor (5ARI) use were assessed. Serum dihydrotestosterone (DHT), total T (TT), free T (FT), follicle stimulating hormone (FSH), luteinizing hormone (LH), Hematocrit (Hct), and lipid levels were extracted and changes during treatment determined. Spearman's rank correlation was used to identify relationships between change in Hct (ΔHct) and study variables. Results Of 179 patients, 49 (27%) developed a ≥10% ΔHct and 36 (20.1%) developed erythrocytosis (Hct ≥50%) at a median follow-up of 7 months. Topical gels were used by 41.3% of patients, injectable T by 52.5%, and subcutaneous pellets by 6.1%. More men who developed ΔHct ≥10% used injectable T than men with ΔHct <10% (65% vs. 48%, p=0.035), and were less likely to be on 5ARI (2% vs. 15%, p=0.017). Men with ΔHct ≥10% had higher post-treatment DHT levels (605.0 vs. 436.0 ng/dL, p=0.017) and lower LH and FSH levels than men with ΔHct <10%. Spearman's rank correlations yielded relationships between ΔHct and post-treatment DHT (ρ=0.258, p=0.001) and TT (ρ=0.171, p=0.023). Conclusion DHT may play a role in TTh-related erythrocytosis, and monitoring of DHT levels during TTh should be considered. In men who develop erythrocytosis, 5ARIs may be therapeutic. Read more at: [URL]https://www.excelmale.com/forum/showthread.php?137-How-to-Manage-Polycythemia-Caused-by-Testosterone-Replacement-Therapy[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
What causes high hematocrit? High DHT?
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top